Department of Leukemia, The University of Texas MD Anderson Cancer Center
Hematology
Dr. Jan A. Burger, MD
|
|
Give Review
Burger works in the field of Hematology. He received awards:"ASCO Career Development Award (CDA)", "Kimmel Scholar Award, Sidney Kimmel Foundation for Cancer Research", "Venia Legendi in Internal Medicine (Privatdozent), Albert-Ludwigs-University Freiburg, Germany", "New Investigator Award, Leukemia Research Foundation", "ASCO Young Investigator Award (YIA)" and "2001Arthur Pappenheim Award of the German Hematology Society (DGHO) for research in the field of hematology/CLL". Doctor Jan A. Burger, MD is also a published MD. He has 103 publication published. The most recent publication is: Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. Burger is registered with Medicare.
Publications
- Outcomes for patients with chronic lymphocytic leukemia and Acute leukemia or myelodysplastic syndrome.
- Pre-BCR signaling in precursor B-cell Acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1, and MYC, and can be targeted by SYK inhibition.
- β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with Chronic lymphocytic...
- BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic Leukemia.
- Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with Acute lymphoblastic leukaemia.
- Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.
- Estimated glomerular filtration rate changes in patients with chronic myeloid Leukemia treated with tyrosine kinase inhibitors.
- Outcomes of patients with chronic lymphocytic Leukemia after discontinuing ibrutinib.
- Self-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia.
- Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells.
- Secondary Mutations as Mediators of Resistance to Targeted Therapy in Leukemia.
- Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed Acute myeloid leukemia.
- The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, with chemoimmunotherapy in patients with chronic lymphocytic Leukemia.
- Three Newly Approved Drugs for Chronic Lymphocytic Leukemia: Incorporating Ibrutinib, Idelalisib, and Obinutuzumab into Clinical Practice.
- A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed / Refractory Acute Lymphoblastic Leukemia.
- Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
- High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic Leukemia is an independent predictor of adverse outcome.
- Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies.
- Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with Chronic lymphocytic leukae...
- Ibrutinib: a paradigm shift in management of CLL.
- Regulation of mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic Leukemia.
- Precision Measurement of the (e^{+}+e^{-}) Flux in Primary Cosmic Rays from 0.5Â GeV to 1Â TeV with the Alpha Magnetic Spectrometer on the International Space Station.
- Safety and activity of ibrutinib plus rituximab for patients with high-risk Chronic lymphocytic leukaemia: a single-arm, phase 2 study.
- Evolution of ibrutinib resistance in chronic lymphocytic Leukemia (CLL).
- Electron and positron fluxes in primary cosmic rays measured with the alpha magnetic spectrometer on the international space station.
- High Statistics Measurement of the Positron Fraction in Primary Cosmic Rays of 0.5-500Â GeV with the Alpha Magnetic Spectrometer on the International Space Station.
- FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic Leukemia.
- Kinetics of chronic lymphocytic Leukemia (CLL) cells in tissues and blood during therapy with the BTK inhibitor ibrutinib.
- STAT3-Activated GM-CSFRalpha Translocates to the Nucleus and Protects CLL Cells from Apoptosis.
- Eradication of bone marrow minimal residual disease with first-line chemoimmunotherapy may prompt early treatment discontinuation in chronic lymphocytic Leukemia.
- Bruton's Tyrosine Kinase: From X-Linked Agammaglobulinemia Toward Targeted Therapy for B-Cell Malignancies.
- The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy Cell leukaemia survival, proliferation and B Cell receptor signalling: a new therapeutic approach.
- Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic Leukemia cells.
- CD49d Is the Strongest Flow Cytometry-Based Predictor of Overall Survival in Chronic Lymphocytic Leukemia.
- Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia.
- Ibrutinib as initial therapy for elderly patients with Chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.
- Phase I and Extension Study of Clofarabine Plus Cyclophosphamide in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
- Molecular Pathways: Targeting the microenvironment in chronic lymphocytic Leukemia- focus on the B cell receptor.
- Bruton's Tyrosine Kinase (BTK) Inhibitors in Clinical Trials.
- A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis.
- Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765).
- The Spiegelmer(R) NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic Leukemia cell motility and causes chemo-sensitization.
- The combination of Hyper-CVAD plus nelarabine as frontline therapy in adult T cell Acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (LL)-MD Anderson c...
- The microenvironment in chronic lymphocytic Leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies.
- Similar Outcome of Patients With Chronic Myeloid Leukemia Treated With Imatinib in or Out of Clinical Trials.
- Significance of deeper molecular responses in patients with chronic myeloid Leukemia in early chronic phase treated with tyrosine kinase inhibitors.
- Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic Leukemia: Analysis of persistent and new-onset cytop...
- B cell receptor signaling in chronic lymphocytic Leukemia.
- Targeting BTK with ibrutinib in relapsed chronic lymphocytic Leukemia.
- Phase II study of azacytidine plus sorafenib in patients with Acute myeloid leukemia and FLT-3 internal tandem duplication mutation.
- Coming full circle: 70 years of chronic lymphocytic Leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling.
- Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia.
- Targeting the microenvironment in chronic lymphocytic Leukemia is changing the therapeutic landscape.
- Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic Leukemia.
- Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic Leukemia B-cell activation and migration.
- Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm Acute myeloid leukemia.
- Twice-Daily Fludarabine and Cytarabine Combination With or Without Gentuzumab Ozogamicin is Effective in Patients With Relapsed/Refractory Acute Myeloid Leukemia, High...
- Recent advances in non-small Cell lung cancer biology and clinical management.
- Bruton's tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic Leukemia cell survival and tissue homing in vitro and in vivo.
- Inhibiting B-Cell Receptor Signaling Pathways in Chronic Lymphocytic Leukemia.
- Th17 and non-Th17 IL-17-expressing cells in chronic lymphocytic Leukemia: delineation, distribution, and clinical relevance.
- Multivariable Model for Time to First Treatment in Patients With Chronic Lymphocytic Leukemia.
- Phosphoinositide 3'-kinase delta: turning off BCR signaling in Chronic Lymphocytic Leukemia..
- The microenvironment in mantle cell Lymphoma: Cellular and molecular pathways and emerging targeted therapies.
- Disrupting the food chain in B cell Lymphomas: co-operation between CXCR4 antagonists and antibodies.
- The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic Leukemia.
- Lenalidomide as initial therapy of elderly patients with chronic lymphocytic Leukemia.
- The microenvironment in hairy cell Leukemia: pathways and potential therapeutic targets.
- CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic Leukemia.
- Nurture versus Nature: The Microenvironment in Chronic Lymphocytic Leukemia.
- The great imitator: systemic nocardiosis mimicking Richter's transformation in relapsed chronic lymphocytic Leukemia.
- Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary Cells.
- Angiopoietin-2 in CLL.
- BCR-mediated decrease of CXCR4 and CD62L in CLL.
- Bendamustine in B-Cell Malignancies: The New 46-Year-Old Kid on the Block.
- Diverse marrow stromal Cells protect CLL Cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal Cell ad...
- The microenvironment in mature B-Cell malignancies: a target for new treatment strategies.
- The lymphatic tissue microenvironments in chronic lymphocytic Leukemia: in vitro models and the significance of CD40-CD154 interactions.
- Long-term outcome of patients with chronic myeloid Leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vit...
- B-cell antigen receptor signaling enhances chronic lymphocytic Leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, ...
- Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic Leukemia: a n...
- Mantle cell Lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting.
- High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic Leukemia B cells in nurselike cell cocultures and after BCR stimulation.
- AT-101 induces apoptosis in CLL B Cells and overcomes stromal Cell-mediated Mcl-1 induction and drug resistance.
- Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic Leukemia.
- CXCR4 is a prognostic marker in Acute myelogenous leukemia.
- CXCR4: a key receptor in the crosstalk between tumor Cells and their microenvironment.
- Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in Chronic lymphocytic leu...
- Expression of functional CCR and CXCR chemokine receptors in podocytes.
- Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic Leukemia.
- The CLL Cell Microenvironment.
- Stromal control of cystine metabolism promotes cancer cell survival in Chronic lymphocytic leukaemia.
- Potential of CXCR4 antagonists for the treatment of metastatic lung cancer.
- Chemokines and chemokine receptors in chronic lymphocytic Leukemia (CLL): from understanding the basics towards therapeutic targeting.
- Modeling the marrow stem Cell niche in vitro: is proximity the key to reproduction?
- CXCR4 chemokine receptor antagonists: perspectives in SCLC.
- CXCR4 in Acute myelogenous leukemia (AML): when too much attraction is bad for you.
- Imatinib mesylate-induced long-term remission in extra-medullary T-cell lymphoid blastic phase of chronic myelogenous Leukemia.
- No cell is an island unto itself: the stromal microenvironment in chronic lymphocytic Leukemia.
- The CXCR4 chemokine receptor in Acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target.
- Autoimmune cytopenias in patients with chronic lymphocytic Leukemia treated with ibrutinib.
- Chronic lymphocytic Leukemia therapy: new targeted therapies on the way.
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Chronic Myeloid Leukemia (CML)
- View All
Doctors Specialties
- Hematology
Accepted Insurances
- Choice Plus POS II
- Amerigroup (Wellpoint)
- Blue Card PPO
- Blue Choice
- Great West Healthcare-Cigna PPO
- Commercial Insurance Company
- Coventry Health Care
- First Health (Coventry Health Care) PPO
- GEHA
- Choice Care PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Awards
- ASCO Career Development Award (CDA)
- Kimmel Scholar Award, Sidney Kimmel Foundation for Cancer Research
- Venia Legendi in Internal Medicine (“Privatdozentâ€Â), Albert-Ludwigs-University Freiburg, Germany
- New Investigator Award, Leukemia Research Foundation
- ASCO Young Investigator Award (YIA)
- 2001 Arthur Pappenheim Award of the German Hematology Society (DGHO) for research in the field of hematology/CLL
Education
-
Albert Ludwigs University Faculty of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1003901612 | |
| NPPES Provider LastName | BURGER | |
| NPPES Provider FirstName | JAN | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 513.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 19.0 | |
| Percent Opioid Claims | 3.7 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1003901612 |
| Last Name Of The Provider | BURGER |
| First Name Of The Provider | JAN |
| View All |
Similar Doctors
|
|
Dr. Stephan J. Dorkhom, DO
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cristina Rodriguez, MD |
|
Dr. Janet E. Macheledt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patrick H. Archie, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ethan A. Natelson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven M. Kornblau, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ulas D. Bayraktar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julie R. Nangia, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cheryl F. Hirsch-Ginsberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James Murray, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott M. Lippman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael H. Kroll, MD |
|
|
Dr. Mohamed T. Elghetany, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gerald S. Cyprus, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lance C. Pagliaro, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark A. Lewis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Martin J. Korbling, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Abhishek V. Marballi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Zahida Yasin, MD
This Doctor is OpenDoctor Recommended.
|